# A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

> **NCT00684593** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 31 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Navarixin 10 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00684593
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-01
- **Primary completion:** 2007-10-01
- **Final completion:** 2007-10-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684593, "A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00684593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*